[Toll-like receptor CD180 and the bone marrow microenvironment as therapeutic targets in multiple myeloma]

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Multiple myeloma (MM) is a challenging malignancy involving malignant plasma cell growth in bone marrow.
• Cell adhesion-mediated drug resistance (CAM-DR) mechanisms are critical for MM patient remission and survival.
• Histone modifications play a role in MM pathogenesis and drug resistance.

Purpose of the Study:

• To investigate the role of histone H3 trimethylation at lysine-27 (H3K27me3) in CAM-DR in MM.
• To identify molecular targets for lenalidomide in preventing MM progression.
• To elucidate the mechanisms of bacterial lipopolysaccharide (LPS) in enhancing MM cell growth.

Main Methods:

• Analysis of H3K27me3 modification in relation to cell adhesion and drug resistance.
• Investigated the role of enhancer of zeste homolog 2 (EZH2) phosphorylation.
• Studied the expression and regulation of CD180, an LPS receptor, in MM cells.
• Promoter analysis to identify transcriptional activators of CD180, including Ikaros (IKZF1).
• Assessed the effect of lenalidomide on LPS-triggered MM cell activation.

Main Results:

• H3K27me3 was identified as a critical histone modification in CAM-DR.
• Cell adhesion inhibited EZH2 phosphorylation, leading to sustained anti-apoptotic gene expression.
• CD180 expression was upregulated by adherence and/or hypoxia, and bacterial LPS enhanced MM cell growth.
• IKZF1 was identified as a key activator of CD180 expression.
• Lenalidomide effectively prevented LPS-triggered MM cell activation by targeting CD180.

Conclusions:

• H3K27me3 and CD180 signaling are important in MM progression and drug resistance.
• Lenalidomide's ability to target CD180 offers a potential strategy to prevent LPS-induced MM disease progression.
• These findings suggest lenalidomide may prolong survival in MM patients by mitigating LPS-driven disease exacerbation.